Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOv18 IgE in Advanced Solid Tumours
NCT02546921Phase 1Completed
- Sponsor
- Cancer Research UK
- Start
- Feb 2016
- Primary completion
- Jun 2021
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of MOv18 IgE in solid tumor (7 cohorts), sponsored by Cancer Research UK. Primary endpoints: Serious Adverse Events and Non-serious Adverse Events Considered to be at Least Possibly Related to MOv18 IgE at 88.5 days, Number of Participants Who Experienced Dose Limiting Toxicities at 3 weeks and 2 more. Started Feb 2016; status: completed.
02
Drugs
MOv18 IgE
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02546921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02546921.